The RevoLix 2 micron continuous wave laser vaporesection for the treatment of high-risk patients with benign prostatic hyperplasia.
Identifieur interne : 000462 ( PubMed/Corpus ); précédent : 000461; suivant : 000463The RevoLix 2 micron continuous wave laser vaporesection for the treatment of high-risk patients with benign prostatic hyperplasia.
Auteurs : Jiemin Si ; Baojun Gu ; Jianjun Yu ; Yuemin XuSource :
- Photomedicine and laser surgery [ 1557-8550 ] ; 2011.
English descriptors
- KwdEn :
- MESH :
- chemical : Thulium.
- instrumentation : Laser Therapy.
- pathology : Prostate, Prostatic Hyperplasia.
- surgery : Prostatic Hyperplasia.
- therapeutic use : Lasers, Gas.
- Aged, Aged, 80 and over, Humans, Male, Organ Size.
Abstract
To evaluate the safety and efficacy of the RevoLix 70W 2 micron continuous wave laser vaporesection in the treatment of high-risk patients with benign prostatic hyperplasia (BPH).
DOI: 10.1089/pho.2009.2748
PubMed: 21182453
Links to Exploration step
pubmed:21182453Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The RevoLix 2 micron continuous wave laser vaporesection for the treatment of high-risk patients with benign prostatic hyperplasia.</title><author><name sortKey="Si, Jiemin" sort="Si, Jiemin" uniqKey="Si J" first="Jiemin" last="Si">Jiemin Si</name><affiliation><nlm:affiliation>Department of Urology, The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.</nlm:affiliation></affiliation></author><author><name sortKey="Gu, Baojun" sort="Gu, Baojun" uniqKey="Gu B" first="Baojun" last="Gu">Baojun Gu</name></author><author><name sortKey="Yu, Jianjun" sort="Yu, Jianjun" uniqKey="Yu J" first="Jianjun" last="Yu">Jianjun Yu</name></author><author><name sortKey="Xu, Yuemin" sort="Xu, Yuemin" uniqKey="Xu Y" first="Yuemin" last="Xu">Yuemin Xu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1089/pho.2009.2748</idno><idno type="RBID">pubmed:21182453</idno><idno type="pmid">21182453</idno><idno type="wicri:Area/PubMed/Corpus">000462</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000462</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The RevoLix 2 micron continuous wave laser vaporesection for the treatment of high-risk patients with benign prostatic hyperplasia.</title><author><name sortKey="Si, Jiemin" sort="Si, Jiemin" uniqKey="Si J" first="Jiemin" last="Si">Jiemin Si</name><affiliation><nlm:affiliation>Department of Urology, The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.</nlm:affiliation></affiliation></author><author><name sortKey="Gu, Baojun" sort="Gu, Baojun" uniqKey="Gu B" first="Baojun" last="Gu">Baojun Gu</name></author><author><name sortKey="Yu, Jianjun" sort="Yu, Jianjun" uniqKey="Yu J" first="Jianjun" last="Yu">Jianjun Yu</name></author><author><name sortKey="Xu, Yuemin" sort="Xu, Yuemin" uniqKey="Xu Y" first="Yuemin" last="Xu">Yuemin Xu</name></author></analytic><series><title level="j">Photomedicine and laser surgery</title><idno type="eISSN">1557-8550</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Laser Therapy (instrumentation)</term><term>Lasers, Gas (therapeutic use)</term><term>Male</term><term>Organ Size</term><term>Prostate (pathology)</term><term>Prostatic Hyperplasia (pathology)</term><term>Prostatic Hyperplasia (surgery)</term><term>Thulium</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Thulium</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Laser Therapy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostate</term><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Gas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Male</term><term>Organ Size</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the safety and efficacy of the RevoLix 70W 2 micron continuous wave laser vaporesection in the treatment of high-risk patients with benign prostatic hyperplasia (BPH).</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21182453</PMID><DateCreated><Year>2011</Year><Month>02</Month><Day>03</Day></DateCreated><DateCompleted><Year>2011</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8550</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Photomedicine and laser surgery</Title><ISOAbbreviation>Photomed Laser Surg</ISOAbbreviation></Journal><ArticleTitle>The RevoLix 2 micron continuous wave laser vaporesection for the treatment of high-risk patients with benign prostatic hyperplasia.</ArticleTitle><Pagination><MedlinePgn>105-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/pho.2009.2748</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the safety and efficacy of the RevoLix 70W 2 micron continuous wave laser vaporesection in the treatment of high-risk patients with benign prostatic hyperplasia (BPH).</AbstractText><AbstractText Label="BACKGROUND DATA" NlmCategory="BACKGROUND">Forty-six high-risk patients (mean age, 82.6 y old) with BPH underwent 2-μm continuous wave laser vaporesection.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The operative time, drop in hemoglobin, drop in serum sodium, indwelling catheterization time, operative complications, international prostatic symptom scores (IPSS), quality of life (QoL), urinary flow rate (Qmax), and post voiding residual urine volume (PVR) were observed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All 46 patients recovered without incident. The mean operative time was 68 ± 16.3 min. Occasional venous hemorrhage occurred during the operation, but no arterial hemorrhage was observed. Hemoglobin decreased from preoperative 15.0 g/dL to postoperative 14.3 g/dL, serum sodium decreased from preoperative 142.4 mmol/L to postoperative 141.6 mmol/L. IPSS decreased from preoperative 22 ± 6.2 to postoperative 9 ± 3.3, QoL scores decreased from 5.1 ± 0.7 to 2.1 ± 0.7, Qmax increased from 8.4 ± 5.2 to 21.2 ± 12.3 mL/sec, PVR decreased from 94.2 ± 60.2 to 21.6 ± 6.4 mL. The parameters were significantly different between pre- and postoperative results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The RevoLix 70W 2-μm continuous wave laser vaporesection is safe and effective in the treatment of high-risk patients with BPH.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Jiemin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Baojun</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jianjun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuemin</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Photomed Laser Surg</MedlineTA><NlmUniqueID>101222340</NlmUniqueID><ISSNLinking>1549-5418</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber><NameOfSubstance UI="D013932">Thulium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053685">Laser Therapy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000295">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054020">Lasers, Gas</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011467">Prostate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013932">Thulium</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2010</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1089/pho.2009.2748</ArticleId><ArticleId IdType="pubmed">21182453</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000462 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000462 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21182453
|texte= The RevoLix 2 micron continuous wave laser vaporesection for the treatment of high-risk patients with benign prostatic hyperplasia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21182453" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |